Business
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE
About this update from Pliant Therapeutics, Inc.
[{"type":"text","content":"Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company’s global medical affairs activities including scientific communications and patient advocacy. “Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease products across a range of therapeutic areas including pulmonary fibrosis,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant. “Gary’s first-hand experience in building best-in-class Medical Affairs organizations will benefit Pliant as we grow our organization and advance our portfolio toward commercial stage.” Dr. Palmer joins Pliant with over 25 years of global leadership experience in medical affairs from biopharmaceutical companies of various sizes and stages, and across multiple therapeutic areas including pulmonary medicine, immunology and neurology. Most recently, Dr. Palmer was Senior Vice President of Global Medical Affairs Immunology & Neuroscience at Bristol Myers Squibb Co (BMS). In this role, Dr. Palmer led the Worldwide Immunology, Fibrosis and Neuroscience Medical Affairs team covering a portfolio spanning 4 globally marketed medications and more than 15 development candidates across the areas of pulmonary fibrosis, dermatology, gastroenterology, rheumatology and neurology. Prior to BMS, Dr. Palmer was Senior Vice President for Medical Affairs at Myovant Sciences, prior to the company being acquired by Sumitomo Pharma, where, in partnership with Pfizer, he supported the launch of new products. Prior to Myovant, Dr. Palmer served as Senior Vice President of U.S. Medical Affairs at Actelion, now a Janssen Pulmonology Company, as Chief Medical Officer for Neuroscience at Eisai Pharmaceuticals, Vice President for Global Development & Medical Affairs at BMS and Vice President of Medical Affairs & Managed Markets at Pfizer. Dr. Palmer earned his M.D. in Family Medicine, and a M.B.A. from the University of the Witwatersrand in Jo...